In a conversation held earlier in the year as the four-year anniversary of the pandemic approached, the pharmaphorum podcast had as guest Murray Aitken, executive director of the
Biopharmaceutical companies across the globe are rapidly expanding their pipelines as they aim to break new ground in different disease areas, on behalf of patients awaiting life-changing t
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh
